Earnings call transcript: Amgen Q1 2026 beats EPS forecast, stock dips

Amgen reported Q1 2026 EPS of $5.15, beating the $4.80 forecast by 7.29%, on revenue of $8.62 billion versus $8.59 billion expected. The company raised full-year 2026 revenue guidance to $37.1 billion-$38.5 billion and EPS guidance to $21.70-$23.10, while increasing its dividend 6% to $2.52 per share. Despite the beat, the stock fell 2.43% after hours as investors focused on patent-expiration pressure, rising R&D spending, and ongoing IRS/tax litigation.

Analysis

The market is treating this as a clean beat, but the more important signal is that Amgen is converting portfolio complexity into durable cash flow while legacy erosion is still manageable. The mix matters: growth is increasingly coming from products with broader prescriber bases and longer duration revenue streams, which should compress the volatility investors typically assign to patent-cliff biotech. The near-term post-earnings dip looks more like digestion of guide quality and tax overhang than a reassessment of the core operating trajectory.

The second-order winner is the “boring” capital return + cash generation story: high margin, rising dividend, and a buyback ceiling create a floor under the stock even if the pipeline takes time to de-risk. The real strategic optionality is MariTide and olpasiran, but those are now being financed by today’s commercial machine rather than requiring the market to underwrite platform risk up front. That changes the equity debate from “can they replace losses?” to “how much upside is embedded if even one of the late-stage programs works,” which is a meaningfully better setup.

The main risk is not execution this quarter; it’s a sequencing risk over the next 2-3 quarters where tax headlines, patent erosion acceleration, and regulatory friction can temporarily obscure the fundamental inflection. Tavneos and the blinatumomab pauses are reminders that pipeline optionality is not linear, and the IRS dispute is the kind of non-operating event that can cap the multiple despite strong fundamentals. In contrast, the consensus may be underweighting the pace at which primary-care adoption can extend Repatha and the broader implication that Amgen is becoming less dependent on specialty-only channels, which should support valuation re-rating over 6-12 months.

Key Decisions for Investors

• Go long AMGN on weakness over the next 1-2 sessions; target a 5-8% rebound as the market digests raised guidance and cash-generation visibility. Stop if the stock breaks the post-earnings low on heavy volume, as that would signal the tax overhang is becoming the dominant narrative.
• Pair trade: long AMGN / short a high-multiple biotech index ETF or basket over 3-6 months. AMGN has self-funded pipeline optionality and capital return support, while the short basket is more exposed to financing risk and data-event volatility.
• Buy AMGN Jan-2027 calls or call spreads to express MariTide/olpasiran optionality with limited downside. Best risk/reward is a 1x2 call spread structure around current levels, monetizing upside if either asset de-risks while capping premium outlay.
• Fade immediate optimism in specialty-only names exposed to cardiometabolic share loss; favor exposure to AMGN over peers with weaker primary-care penetration. The second-order winner is the company that can sell through PCPs, not just specialists.
• If AMGN rallies into the next IRS headline, consider trimming 25-30% of position into strength and re-adding on any tax-related drawdown. The litigation can create sharp but temporary dislocations that are attractive entry points.